Variability of three activated clotting time point-of-care systems in cardiac surgery: reinforcing available evidence

被引:1
|
作者
Solis Clavijo, Diego [1 ]
Ortega Cotano, Abel [1 ]
Alonso Pena, Nuria [2 ]
Caballero Galvez, Sergio [1 ]
Arellano Nunez, Fernando [1 ]
Carballo Caro, Juan Manuel [1 ]
Munoz-Cacho, Pedro [3 ]
Tocon Ale, Cristina [1 ]
机构
[1] Virgen Rocio Univ Hosp, Ave Marie Curie 3,Portal 6 3 B, Seville 41927, Spain
[2] Marques Valdecilla Univ Hosp, Cardiovasc Surg Area, Santander, Cantabria, Spain
[3] Cantabrian Hlth Serv, Cantabria, Spain
来源
PERFUSION-UK | 2022年 / 37卷 / 07期
关键词
activated clotting time; anticoagulant drugs; blood coagulation test; point-of-care systems;
D O I
10.1177/02676591211023687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac surgery with extracorporeal circulation (ECC) requires the administration of anticoagulant drugs to maintain ACT ranges 400-600 seconds, which requires exhaustive coagulation monitoring for which various point-of-care devices are available. However, there is variability between them, so we aimed to compare the values in ACT measurement. Methods: Simultaneous ACT measurements were performed with the Hemochron Response(R), Hemostasis Management System Plus(R) (HMS Plus(R)) and Hemochron Signature(R) systems. Results: A total of 255 simultaneous measurements were taken, the mean and standard deviation (SD) of each device were: Hemochron Signature(R) 361.1 seconds (SD: 156.9), HMS Plus(R) 412.8 seconds (SD: 180.9) and Hemochron Response(R) 422.8 seconds (SD: 187.9), being these differences statistically significant (Fridman's test p < 0.01). For comparisons the Bland-Altman method was used, resulting the Hemochron Response(R) has 61.7 seconds higher mean values than the Hemochron Signature(R), the Hemochron Response(R) 10 seconds higher than the HMS Plus(R) and the HMS Plus(R) 51.7 seconds higher than the Hemochron Signature(R). Conclusion: The differences found in comparisons are considered to be clinically relevant, which is why it is considered important to make the variability of the different monitoring systems known and to take them into account for optimal control of this parameter and its clinical repercussions.
引用
收藏
页码:711 / 714
页数:4
相关论文
共 50 条
  • [1] Streamlining Activated Clotting Time Measuring Systems: Comparison of Three Point-of-Care Systems to the i-STAT.
    Lynn, Beth
    Filipova, Lora
    Suh-Lailam, Brenda
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147
  • [2] Interchangeability of Activated Clotting Time Values Across Different Point-of-Care Systems
    Thenappan, Thenappan
    Swamy, Rajiv
    Shah, Atman
    Nathan, Sandeep
    Nichols, Jearlyn
    Bond, Linda
    Jolly, Neeraj
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (09): : 1379 - 1382
  • [3] A Multicenter Comparison of 2 Point-of-Care Activated Clotting Time Test Systems
    Kemna, Evelien W. M.
    Schellings, Mark W. M.
    Vlachojannis, Georgios J.
    Falter, Florian
    Milane-Santman, Antoinette
    Hesselink, Tim
    Scholten, Marcoen
    Krabbe, Johannes G.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2019, 4 (03): : 468 - 470
  • [4] A two site comparison of two point-of-care activated clotting time systems
    Kemna, Evelien W. M.
    Kuipers, Charline
    Luttikhuis-Spanjer, Agnes M. A. Oude
    Majoor, Stefan
    Boudrie, Renate
    Speekenbrink, Ron G. H.
    Hoffman, Reinhard
    Krabbe, Johannes G.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (01) : E13 - E16
  • [5] Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration
    Casserly, IP
    Kereiakes, DJ
    Gray, WA
    Gibson, PH
    Lauer, MA
    Reginelli, JP
    Moliterno, DJ
    THROMBOSIS RESEARCH, 2004, 113 (02) : 115 - 121
  • [6] Correlation of point-of-care ecarin clotting time versus activated clotting time with Bivalirudin concentrations
    Cho, L
    Kottke-Marchant, K
    Lincoff, AM
    Roffi, M
    Reginelli, JP
    Kaldus, T
    Moliterno, DJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (09): : 1110 - 1113
  • [7] Reference interval, longitudinal variability and reliability of activated clotting time in healthy dogs using a point-of-care analyser
    Hellemans, Arnaut
    Devriendt, Nausikaa
    De Somer, Filip
    Marynissen, Sofie
    Daminet, Sylvie
    Paepe, Dominique
    Smets, Pascale
    VETERINARY MEDICINE AND SCIENCE, 2023, 9 (04) : 1534 - 1540
  • [8] Three best point-of-care tools available
    MacDonell, Karen
    BRITISH COLUMBIA MEDICAL JOURNAL, 2022, 64 (03): : 131 - 131
  • [9] Evaluation of a point-of-care coagulation analyzer for measurement of prothrombin time, activated partial thromboplastin time, and activated clotting time in dogs
    Tseng, LW
    Hughes, D
    Giger, U
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2001, 62 (09) : 1455 - 1460
  • [10] Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability
    Daniel Dirkmann
    Elisabeth Nagy
    Martin W. Britten
    Jürgen Peters
    BMC Anesthesiology, 19